| 0.63 0.005 (0.78%) | 08-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.79  |
1-year : | 0.87 |
| Resists | First : | 0.68 |
Second : | 0.75 |
| Pivot price | 0.61 |
|||
| Supports | First : | 0.56 | Second : | 0.47 |
| MAs | MA(5) : | 0.61 |
MA(20) : | 0.62 |
| MA(100) : | 0.82 |
MA(250) : | 1.09 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 43.6 |
D(3) : | 32.4 |
| RSI | RSI(14): 45.8 |
|||
| 52-week | High : | 2.78 | Low : | 0.56 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RDHL ] has closed below upper band by 33.4%. Bollinger Bands are 50.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.65 - 0.65 | 0.65 - 0.65 |
| Low: | 0.59 - 0.6 | 0.6 - 0.6 |
| Close: | 0.62 - 0.63 | 0.63 - 0.63 |
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.
Mon, 17 Aug 2026
Redhill Biopharma (RDHL) Holds Near $0.60 as Shares Stabilize Above Key Support - Anchored VWAP - vinanet.vn
Sat, 15 Aug 2026
Redhill Biopharma (RDHL) Rises 0.84% to $0.60 as Stock Holds Within Established Range - Fibonacci Extension - vinanet.vn
Fri, 07 Aug 2026
RedHill Biopharma (RDHL) investors back all AGM resolutions in 2026 - Stock Titan
Thu, 06 Aug 2026
RedHill Biopharma (NASDAQ: RDHL) adjourns AGM after quorum shortfall - Stock Titan
Sat, 25 Jul 2026
Redhill Biopharma Ltd. Revenue Breakdown – NASDAQ:RDHL - TradingView
Fri, 17 Jul 2026
RedHill Biopharma (RDHL) Edges Higher: Stock Tests Support at $0.70 - Weekly Profile - po-news-eg.net
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 4.2e+006 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 14 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.79e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -150 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 765.3 % |
| Return on Equity (ttm) | -22.8 % |
| Qtrly Rev. Growth | 286000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 58367.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 3.67 |
| Dividend | 0 |
| Forward Dividend | 20000 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|